 |
|
Treatment of Cutaneous Warts With Squaric Acid Dibutylester: A Decade of Experience
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Treatment of recurrent cutaneous warts is often troublesome. Contact immunotherapy with squaric acid dibutylester (SADBE) has been used with good results, but in a limited number of patients and without follow-up data.1-3
Subjects, Materials, and Methods
From January 1986 to December 1996, 568 patients (404 adults and 164 children) with multiple and resistant warts were enrolled at our institution to be treated with contact immunotherapy with SADBE. Included in the study were those patients who satisfied at least 2 of the following criteria: single or multiple sites with several warts, warts resistant to repeated medical and/or surgical treatments, recurrent multiple warts, and patient refusal to undergo any type of destructive or surgical treatment. Excluded from the study were patients with warts located exclusively on the face, children younger than 2 years, and pregnant or breastfeeding women. The first sensitization was carried out by topical application of 3% SADBE in acetone to the lesions. After . . . [Full Text of this Article]
Results
Comment
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Adult and paediatric contact immunotherapy with squaric acid dibutylester (SADBE) for recurrent, multiple, resistant, mucocutaneous anogenital warts
Dall' Oglio et al.
Sex. Transm. Infect. 2002;78:309-310.
FULL TEXT
|
